We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+5.33%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.83B
AUM Growth
+$233M
(+9%)
Cap. Flow
+$131M
Cap. Flow
% of AUM
4.64%
Top 10 Holdings %
Top 10 Hldgs %
38.82%
Holding
108
New
54
Increased
16
Reduced
13
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Danaher
DHR
|
+$123M |
| 2 |
Incyte
INCY
|
+$96M |
| 3 |
Encompass Health
EHC
|
+$82.4M |
| 4 |
Petco
WOOF
|
+$73.5M |
| 5 |
Zoetis
ZTS
|
+$66.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$100M |
| 2 |
Cooper Companies
COO
|
+$88.2M |
| 3 |
Aurinia Pharmaceuticals
AUPH
|
+$86.9M |
| 4 |
Bio-Rad Laboratories Class A
BIO
|
+$81.7M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$80.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.85% |
| 2 | Real Estate | 4.52% |
| 3 | Consumer Discretionary | 2.42% |
| 4 | Financials | 1.56% |
| 5 | Technology | 1.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KIN
76
DELISTED
Kindred Biosciences, Inc.
KIN
| $1.32M | 0.05% |
+265,580
| New | +$1.28M |
|
|
MRUS
77
DELISTED
Merus
MRUS
| $1.26M | 0.04% |
+60,490
| New | +$1.4M |
|
|
CNTB
78
Connect Biopharma Holdings
CNTB
$139M
| $1.11M | 0.04% |
+60,000
| New | +$1.02M |
|
79
Omeros
OMER
$959M
| $890K | 0.03% |
+50,000
| New | +$972K |
|
80
MoonLake Immunotherapeutics
MLTX
$1.55B
| $613K | 0.02% |
+60,027
| New | +$662K |
|
81
Anika Therapeutics
ANIK
$287M
| $552K | 0.02% |
13,540
-6,780
| -33% | -$257K |
|
|
MREO
82
Mereo BioPharma
MREO
$47.3M
| $503K | 0.02% |
+149,170
| New | +$527K |
|
83
Tango Therapeutics
TNGX
$4.41B
| $456K | 0.02% |
+41,032
| New | +$472K |
|
|
AMRN
84
Amarin Corp
AMRN
$303M
| – | – |
-19,638
| Closed | -$1.92M |
|
|
85
Bio-Rad Laboratories Class A
BIO
$9.42B
| – | – |
-140,080
| Closed | -$81.7M |
|
|
86
Bristol-Myers Squibb
BMY
$132B
| – | – |
-1,297,700
| Closed | -$80.5M |
|
87
Certara
CERT
$1.25B
| – | – |
-150,000
| Closed | -$5.06M |
|
88
Cigna
CI
$74.6B
| – | – |
-8,502
| Closed | -$1.77M |
|
89
Charles River Laboratories
CRL
$12.8B
| – | – |
-107,800
| Closed | -$26.9M |
|
90
Edwards Lifesciences
EW
$51.7B
| – | – |
-321,200
| Closed | -$29.3M |
|
|
FOLD
91
PUT
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-250,000
| Closed | -$5.77M |
|
|
HOLX
92
DELISTED
Hologic
HOLX
| – | – |
-1,017,280
| Closed | -$74.1M |
|
93
Johnson & Johnson
JNJ
$625B
| – | – |
-435,010
| Closed | -$68.5M |
|
94
LivaNova
LIVN
$4.2B
| – | – |
-616,030
| Closed | -$40.8M |
|
|
95
Madrigal Pharmaceuticals
MDGL
$11.8B
| – | – |
-902,601
| Closed | -$100M |
|
96
Neurocrine Biosciences
NBIX
$16.6B
| – | – |
-226,460
| Closed | -$21.7M |
|
97
Omega Healthcare
OHI
$14.7B
| – | – |
-770,910
| Closed | -$28M |
|
98
Teleflex
TFX
$5.98B
| – | – |
-13,150
| Closed | -$5.41M |
|
99
Tenet Healthcare
THC
$21.1B
| – | – |
-431,441
| Closed | -$17.2M |
|
100
UnitedHealth
UNH
$370B
| – | – |
-174,990
| Closed | -$61.4M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2021 Portfolio in Review
As of Q1 2021, HealthCor Management held 108 positions worth $2.83B, up 9% from $2.59B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
HealthCor Management deployed $131M of net new capital in Q1 2021, opening 54 new positions and adding to 16 existing holdings. Its largest new stake was Danaher: 604,236 shares worth $121M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 92% a quarter earlier, followed by Real Estate and Consumer Discretionary.
On the sell side, the largest reduction was Cooper Companies, an estimated $88.2M trimmed.
- HealthCor Management's largest Q1 2021 buy was Danaher: 604,236 shares worth $121M.
- HealthCor Management added most to Incyte in Q1 2021, an estimated $96M increase.
- HealthCor Management's biggest Q1 2021 reduction was Cooper Companies, cutting an estimated $88.2M.
- HealthCor Management fully exited Madrigal Pharmaceuticals in Q1 2021, selling an estimated $100M.
- HealthCor Management's ten largest holdings make up 39% of its $2.83B portfolio in Q1 2021.
- HealthCor Management opened 54 new positions and closed 25 in Q1 2021.
- HealthCor Management's portfolio value rose 9% quarter-over-quarter to $2.83B.
Based on HealthCor Management's 13F filing for Q1 2021, filed 17 May 2021.